Sökning: id:"swepub:oai:gup.ub.gu.se/249394" > Consensus report: f...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 05669naa a2200793 4500 | |
001 | oai:gup.ub.gu.se/249394 | |
003 | SwePub | |
008 | 240528s2017 | |||||||||||000 ||eng| | |
009 | oai:DiVA.org:oru-53881 | |
024 | 7 | a https://gup.ub.gu.se/publication/2493942 URI |
024 | 7 | a https://doi.org/10.1111/apt.138682 DOI |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-538812 URI |
040 | a (SwePub)gud (SwePub)oru | |
041 | a eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a König, Julia,d 1983-u Örebro universitet,Institutionen för medicinska vetenskaper,NGBI4 aut0 (Swepub:oru)jkg |
245 | 1 0 | a Consensus report: faecal microbiota transfer - clinical applications and procedures |
264 | c 2016-11-27 | |
264 | 1 | a Hoboken, USA :b Wiley,c 2017 |
500 | a Funding Agencies:Seres TherapeuticsAbbVieAstellasBiogenJanssenMSDMundipharmaTakeda Summit TherapeuticsFalkFoundationTakeda | |
520 | a Background Faecal microbiota transplantation or transfer (FMT) aims at replacing or reinforcing the gut microbiota of a patient with the microbiota from a healthy donor. Not many controlled or randomised studies have been published evaluating the use of FMT for other diseases than Clostridium difficile infection, making it difficult for clinicians to decide on a suitable indication. To provide an expert consensus on current clinical indications, applications and methodological aspects of FMT. Well-acknowledged experts from various countries in Europe have contributed to this article. After literature review, consensus has been achieved by repetitive circulation of the statements and the full manuscript among all authors with intermittent adaptation to comments (using a modified Delphi process). Levels of evidence and agreement were rated according to the GRADE system. Consensus was defined a priori as agreement by at least 75% of the authors. Key recommendations include the use of FMT in recurrent C. difficile infection characterised by at least two previous standard treatments without persistent cure, as well as its consideration in severe and severe-complicated C. difficile infection as an alternative to total colectomy in case of early failure of antimicrobial therapy. FMT in inflammatory bowel diseases (IBD), irritable bowel syndrome (IBS) and metabolic syndrome should only be performed in research settings. Faecal microbiota transplantation or transfer is a promising treatment for a variety of diseases in which the intestinal microbiota is disturbed. For indications other than C. difficile infection, more evidence is needed before more concrete recommendations can be made. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicin0 (SwePub)3022 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicine0 (SwePub)3022 hsv//eng |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Gastroenterologi0 (SwePub)302132 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Gastroenterology and Hepatology0 (SwePub)302132 hsv//eng |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Medicinska och farmaceutiska grundvetenskaperx Farmakologi och toxikologi0 (SwePub)301022 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Basic Medicinex Pharmacology and Toxicology0 (SwePub)301022 hsv//eng |
653 | a clostridium-difficile infection | |
653 | a irritable-bowel-syndrome | |
653 | a randomized | |
653 | a controlled-trial | |
653 | a human intestinal microbiota | |
653 | a active | |
653 | a ulcerative-colitis | |
653 | a term-follow-up | |
653 | a crohns-disease | |
653 | a gut microbiota | |
653 | a nasogastric tube | |
653 | a transplantation | |
653 | a Gastroenterology & Hepatology | |
653 | a Pharmacology & Pharmacy | |
653 | a arkey jm | |
653 | a 1989 | |
653 | a jama-journal of the american medical association | |
653 | a v262 | |
653 | a p3452 | |
700 | 1 | a Siebenhaar, A.u Hamburg, Germany4 aut |
700 | 1 | a Hogenauer, C.u Graz, Austria4 aut |
700 | 1 | a Arkkila, P.u Helsinki, Finland4 aut |
700 | 1 | a Nieuwdorp, Maxu Gothenburg University,Göteborgs universitet,Wallenberglaboratoriet,Wallenberg Laboratory,Amsterdam, The Netherlands; Gothenburg, Sweden4 aut0 (Swepub:gu)xnieum |
700 | 1 | a Norén, Torbjörn,d 1955-u Örebro universitet,Institutionen för medicinska vetenskaper4 aut0 (Swepub:oru)trnn |
700 | 1 | a Ponsioen, C. Y.u Amsterdam, The Netherlands4 aut |
700 | 1 | a Rosien, U.u Hamburg, Germany4 aut |
700 | 1 | a Rossen, N. G.u Amsterdam, The Netherlands4 aut |
700 | 1 | a Satokari, R.u Helsinki, Finland4 aut |
700 | 1 | a Stallmach, A.u Jena, Germany4 aut |
700 | 1 | a de Vos, W.u Helsinki, Finland; Wageningen, The Netherlands4 aut |
700 | 1 | a Keller, J.u Hamburg, Germany4 aut |
700 | 1 | a Brummer, Robert Jan,d 1957-u Örebro universitet,Institutionen för medicinska vetenskaper,NGBI4 aut0 (Swepub:oru)rnbr |
710 | 2 | a Örebro universitetb Institutionen för medicinska vetenskaper4 org |
773 | 0 | t Alimentary Pharmacology & Therapeuticsd Hoboken, USA : Wileyg 45:2, s. 222-239q 45:2<222-239x 0269-2813x 1365-2036 |
856 | 4 | u https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/apt.13868 |
856 | 4 | u https://doi.org/10.1111/apt.13868y Fulltext |
856 | 4 | u https://oru.diva-portal.org/smash/get/diva2:1055385/FULLTEXT01.pdfx primaryx Raw objecty fulltext:print |
856 | 4 8 | u https://gup.ub.gu.se/publication/249394 |
856 | 4 8 | u https://doi.org/10.1111/apt.13868 |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-53881 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.